Biomedical Engineering Reference
In-Depth Information
157. Cuzick J et al (2011) Preventive therapy for breast cancer: a consensus statement. Lancet
Oncol 12(5):496-503
158. Jensen EV et al (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer
Res 9:1980-1989
159. Riggs BL et al (2003) Selective estrogen-receptor modulators - mechanisms of action and
application to clinical practice. N Engl J Med 348:618-629
160. Nilsson S et al (2005) Oestrogen receptors and selective oestrogen receptor modulators:
molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 96:15-25
161. Orlando L et al (2010) Molecularly targeted endocrine therapies for breast cancer. Cancer
Treat Rev 36(Suppl 3):S67-S71
162. Johnson MD et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl
tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159
163. Lim YC et al (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic
effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother
Pharmacol 55:471-478
164. Lim YC et al (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen
induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
J Pharmacol Exp Ther 318:503-512
165. Goetz MP et al (2008) Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of
drug response. Clin Pharmacol Ther 83:160-166
166. Wu X et al (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets
estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722-1727
167. Wu X et al (2011) Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic
actions of endoxifen. Breast Cancer Res 13:R27
168. Crewe HK et al (1997) Variable contribution of cytochromes P450 2D6, 2 C9 and 3A4 to the
4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171-178
169. Coller JK et al (2002) The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the
formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin
Pharmacol 54:157-167
170. Crewe HK et al (2002) Metabolism of tamoxifen by recombinant human cytochrome P450
enzymes: formation of the 4-hydroxy, 4ยข-hydroxy and N-desmethyl metabolites and isomer-
ization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869-874
171. Desta Z et al (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by
the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
J Pharmacol Exp Ther 310:1062-1075
172. Jin Y et al (2005) CYP2D6 Genotype, antidepressant use, and tamoxifen metabolism during
adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
173. Madlensky L et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and
breast cancer outcomes. Clin Pharmacol Ther 89:718-725
174. Zheng Y et al (2007) Elimination of antiestrogenic effects of active tamoxifen metabolites by
glucuronidation. Drug Metab Dispos 35:1942-1948
175. Kaku T et al (2004) Quaternary ammonium-linked glucuronidation of tamoxifen by human
liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 67:2093-2102
176. Ogura K et al (2006) Quaternary ammonium-linked glucuronidation of trans-4-hydroxyta-
moxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-
glucuronosyltransferase 1A4. Biochem Pharmacol 71:1358-1369
177. Sun D et al (2006) Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation
by human UGT1A4 variants. Breast Cancer Res 8:R50
178. Benoit-Biancamano MO, et al. (2009) A pharmacogenetics study of the human glucuronosyl-
transferase UGT1A4. Pharmacogenet Genomics [Epub ahead of print]
179. Sun D et al (2007) Glucuronidation of active tamoxifen metabolites by the human UDP
glucuronosyltransferases. Drug Metab Dispos 35:2006-2014
180. Blevins-Primeau AS et al (2009) Functional signi fi cance of UDP-glucuronosyltransferase
variants in the metabolism of active tamoxifen metabolites. Cancer Res 69:1892-1900
